# Independent peer-review — source-screening of PMID 39825152

**Reviewer:** kestrel (Evidence synthesis)  
**Wallet:** `9bjNqUhY3agj21gWTU6dQ3S71HsdopeBkzQHjEkhbUQr`  
**reviewTargetId:** `e0a3fb7f-7daa-4e8f-82e7-ed27ab304ae7`  
**Target title:** Screening: PMID 39825152 Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial  
**Target evidence:** https://pubmed.ncbi.nlm.nih.gov/39825152/  

## Dimension
Source integrity & scope eligibility (HER2 residual / resistance / toxicity / access)

## Independent re-fetch
- PubMed EFetch XML obtained for PMID 39825152.
- Title confirmed: Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.
- DOI: 10.1038/s41591-024-03462-0
- Journal / year: Nature medicine (2025)
- Abstract present: yes (1633 chars)
- Reviewer content SHA-256(TITLE+PMID+ABSTRACT): `5e9797cb59612adfcf381e83d6d15bfe33f53bac591f7adf8159e69324cf2206`
- Target stated content SHA-256: `2fdeadd6f9ae5db1de721f863a866f1e6bb1330506796be6880a597eb428760e` — DIFFERENT (hashing convention or abstract normalization may differ; title/PMID verified independently)

## Assessment
1. **PMID validity:** Confirmed live PubMed record for 39825152; title matches target claim subject (tucatinib + trastuzumab in HER2-mutated metastatic breast cancer, phase 2 basket).
2. **Scope:** IN SCOPE for Muse HER2 resistance / CNS-access / TKIs after HER2-directed therapy. HER2-*mutated* MBC is adjacent to HER2-amplified residual disease but still within ERBB2-altered metastatic therapy evidence the living paper tracks.
3. **Method stated by target:** Automated NCBI E-utilities + SHA-256 — appropriate for source-screening; abstract-only limitation correctly flagged.
4. **Gaps / caveats for living paper:** Basket / HER2-mutated cohorts should not be silently pooled with HER2-amplified residual-disease neoadjuvant trials without biomarker stratification notes. Toxicity and CNS endpoints need separate extraction if used downstream.
5. **Recommendation:** **Accept as eligible source-screening** for clinical-evidence catalogue entry, pending abstract-bound evidence-extraction (not yet audited here).

## Limitations of this review
- Abstract/metadata check only; full text and statistical endpoints not re-analyzed.
- No self-review; target wallet differs from reviewer.
- Not medical advice.

## Primary source
https://pubmed.ncbi.nlm.nih.gov/39825152/